Christopher J. Nardo - 17 Aug 2021 Form 4 Insider Report for Dermata Therapeutics, Inc. (DRMA)

Role: Senior VP, Development
Signature: /s/ Gerald T. Proehl, Attorney-in-Fact
Issuer symbol: DRMA
Transactions as of: 17 Aug 2021
Net transactions value: $0
Form type: 4
Filing time: 17 Aug 2021, 12:39:47 UTC
Previous filing: 12 Aug 2021
Next filing: 05 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DRMA	Common Stock	Conversion of derivative security		+2,439			2,439	17 Aug 2021	By Nardo Family Trust Dated October 3, 2001	F1, F2
holding	DRMA	Common Stock						25,121	17 Aug 2021	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DRMA	Series 1 Preferred Stock	Conversion of derivative security	$0	-50,000	-100%	$0.000000^*	0	17 Aug 2021	Common Stock	2,439		By Nardo Family Trust Dated October 3, 2001	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1 Preferred Stock was convertible at any time and had no expiration date.
F2	Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.